Trial Profile
Non-Interventional Study to Investigate Efficacy and Safety of Nab-Paclitaxel in Patients With Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jun 2018
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms Nabucco
- Sponsors iOMEDICO AG
- 12 Sep 2017 Final results of the study assessing overall survival and quality of life, presented at the 42nd European Society for Medical Oncology Congress.
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 11 Oct 2016 Results of effectiveness analyses by treatment line presented at the 41st European Society for Medical Oncology Congress